References
1. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.The Lancet. 2014;383(9922):1041-1048.
2. Lancet EBCTCGJT. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. 2015;386(10001):1341-1352.
3. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment—associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clinical breast cancer.2006;7(2):127-132.
4. Sabel MS. Chapter 17 - Principles of Adjuvant Hormonal Therapy. In: Sabel MS, ed. Essentials of Breast Surgery. Mosby; 2009:267-278.
5. The A. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.The Lancet. 2002;359(9324):2131-2139.
6. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of Clinical Oncology.2007;25(25):3877-3883.
7. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause (New York, NY). 2007;14(6):995.
8. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho‐Oncology.2012;21(1):43-53.
9. So WK, Marsh G, Ling W, et al. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Paper presented at: Oncology nursing forum2009.
10. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast cancer research and treatment. 2006;100(3):273-284.
11. Baglia ML, Lin IH, Cartmel B, et al. Endocrine‐related quality of life in a randomized trial of exercise on aromatase inhibitor‐induced arthralgias in breast cancer survivors. Cancer. 2019.
12. Snaith RP. The hospital anxiety and depression scale. Health and quality of life outcomes. 2003;1(1):1-4.
13. Harris SR, Schmitz KH, Campbell KL, McNeely ML. Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals. Cancer.2012;118(S8):2312-2324.
14. Reyes-Gibby CC, Anderson KO, Morrow PK, Shete S, Hassan S. Depressive symptoms and health-related quality of life in breast cancer survivors. Journal of women’s health. 2012;21(3):311-318.
15. Holland JC, Bultz BD. The NCCN guideline for distress management: a case for making distress the sixth vital sign. Journal of the National Comprehensive Cancer Network. 2007;5(1):3-7.
16. Jacobson E. Progressive muscle relaxation. Interview Behaviour” Journal of Abnormal Psy-University of Chicago Piess, Chicago chology. 1938;75(1):18.
17. Bell JA, Saltikov JB. Mitchell’s relaxation technique: Is it effective? Physiotherapy. 2000;86(9):473-478.
18. Bernstein DA, CARLSON CR, SCHMIDT JE. Progressive relaxation.Stress Management. 1973:88.
19. Otman A, Köse N. Egzersiz tedavisinde temel prensipler ve yöntemler.Meteksan AŞ. 2006:21-51.
20. Kurt B, Kapucu S. The effect of relaxation exercises on symptom severity in patients with breast cancer undergoing adjuvant chemotherapy: An open label non-randomized controlled clinical trial.European Journal of Integrative Medicine. 2018;22:54-61.
21. Hojan K, Molińska-Glura M, Milecki P. Physical activity and body composition, body physique, and quality of life in premenopausal breast cancer patients during endocrine therapy–a feasibility study.Acta Oncologica. 2013;52(2):319-326.
22. Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis. Supportive Care in Cancer.2020;28(4):1587-1596.
23. Galantino ML, Desai K, Greene L, DeMichele A, Stricker CT, Mao JJJICT. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor–associated arthralgias. 2012;11(4):313-320.
24. Dicle A, Karayurt Ö, Dirimese EJPMN. Validation of the Turkish version of the Brief Pain Inventory in surgery patients. 2009;10(2):107-113. e102.
25. Cleeland C, Ryan KJA, Academy of Medicine, Singapore. Pain assessment: global use of the Brief Pain Inventory. 1994.
26. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. 1997;15(3):974-986.
27. Aydemir OJTPD. Hastane anksiyete ve depresyon olcegi Turkce formunun gecerlilik ve guvenilirligi. 1997;8:187-280.
28. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor–associated arthralgia and/or bone pain: frequency and characterization in non–clinical trial patients. Clinical breast cancer. 2007;7(10):775-778.
29. Laroche F, Coste J, Medkour T, et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. The Journal of Pain.2014;15(3):293-303.
30. Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL. Interventions for the Treatment of Aromatase Inhibitor–Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis. Cancer nursing. 2017;40(4):E26-E41.
31. DeNysschen C, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’connor T. Exercise intervention in breast cancer patients with aromatase inhibitor‐associated arthralgia: a pilot study. European journal of cancer care. 2014;23(4):493-501.
32. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.J Clin Oncol. 2015;33(10):1104-1111.
33. Paulo TR, Rossi FE, Viezel J, et al. The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial. Health and Quality of Life Outcomes. 2019;17(1):17.
34. Fields J, Richardson A, Hopkinson J, Fenlon D. Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor–associated arthralgia: a feasibility study. Journal of pain and symptom management. 2016;52(4):548-559.
35. Galantino ML, Callens ML, Cardena GJ, Piela NL, Mao JJ. Tai Chi for Well-being of Breast Cancer Survivors With Aromatase Inhibitor-associated Arthralgias: A Feasibility Study. Alternative Therapies in Health & Medicine. 2013;19(6).
36. Greenlee H, DuPont‐Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment. CA: a cancer journal for clinicians. 2017;67(3):194-232.
37. Lyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. Journal of Clinical Oncology.2018;36(25):2647-2655.
38. Gerritsen JK, Vincent AJ. Exercise improves quality of life in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. British Journal of Sports Medicine.2016;50(13):796-803.
39. Shobeiri F, Masoumi SZ, Nikravesh A, Moghadam RH, Karami M. The impact of aerobic exercise on quality of life in women with breast cancer: a randomized controlled trial. Journal of research in health sciences. 2016;16(3):127.
40. Zhang X, Li Y, Liu D. Effects of exercise on the quality of life in breast cancer patients: a systematic review of randomized controlled trials. Supportive Care in Cancer. 2019;27(1):9-21.
41. Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer.2009;18(4):343-352.